Melanotan I

Melanotan I, known medically as Afamelanotide and sold as Scenesse for a specific approved indication, is a synthetic melanocortin-1 receptor agonist. Compared to Melanotan II, it is more selective in how it acts on melanocortin receptors, producing tanning and UV-protective effects with a cleaner side effect profile. How it works: MT-1 specifically activates the melanocortin-1 receptor, which is the primary receptor driving skin pigmentation. This stimulates melanin production and provides photoprotection by preparing the skin's defense mechanisms ahead of sun exposure. Because it is more receptor-selective than MT-2, it does not carry the same degree of libido and other off-target effects. Who tends to use it: MT-1 is used by people seeking a skin tan with better sun protection, particularly those who want a cleaner profile than MT-2 offers. It has a primary tanning goal and a secondary skin health goal. People with photosensitivity disorders are the approved population for its Scenesse form. What to expect: MT-1 produces nausea less frequently than MT-2. Tanning develops over a seasonal course of treatment. The Scenesse form is an implant administered in a clinical setting; compounded forms are injected. How it is taken: MT-1 is given by subcutaneous injection or as a subcutaneous implant, in a course-based format. Timing is ahead of anticipated sun exposure. Cycles are seasonal in nature. Exact dose is set per protocol. Safety notes: Mole monitoring is required, as with any melanocortin tanning agent. Nausea is possible but less pronounced than with MT-2. MT-1 is excluded for people with a cancer history. Scenesse is FDA-approved for a rare photosensitivity disorder (erythropoietic protoporphyria) but off-label use for general tanning is not approved. Appropriate use, dose, and safety screening are determined at a PepDepo consultation.